Alkermes
artistry combination cohorts enrollment completed | Alkermes
Company
Deck Type
Sector
Industry
Deck date
June 2021
Slide
16 of 31
Similar slides by Alkermes
See diffirences between slides (animation)
Results
June 2021
artistry study design | Alkermes
Related slides by other companies
BioAtla
Investor Presentation
August 2022
phase results with support advancing into phase | BioAtla
BioAtla
Investor Presentation
August 2023
phase results with support advancing into phase | BioAtla
BioAtla
Investor Presentation
January 2024
phase cab demographics tumor types | BioAtla
Recursion Pharmaceuticals
Investor Day
January 2023
clinical patient population large and diagnosable rare autosomal dominant tumor syndrome resulting from inactivation of the gene which leads to deficiencies in the tumor suppressor protein merlin can be inherited or spontaneous of patients represent new mutations up to are mosaic manifestations and vestibular mean age at presentation years no approved medical therapy no approved drugs for surgery is standard of care when feasible location may make complete resection untenable leading to hearing loss facial paralysis poor balance and visual difficulty disease overview neurofibromatosis type | Recursion Pharmaceuticals
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights